Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
暂无分享,去创建一个
P. Dubus | V. Praloran | I. Dusanter-Fourt | B. Rousseau | A. Bidet | N. Milpied | O. Kosmider | L. Casetti | A. Pigneux | A. Guitart | J. Pasquet | B. Izac | Alban Giese | C. Naudin | I. Vigon | V. Desplat | A. Villacreces | P. Dumas | O. Mansier | A. Artus | M. Dufossée | S. Martin-Lannerée
[1] H. Kantarjian,et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. , 2018, Blood.
[2] D. Edwards,et al. HIF1α drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia , 2018, Oncogene.
[3] Jisung Park,et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia , 2018, Leukemia.
[4] R. Larson,et al. Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study , 2017, The Lancet. Oncology.
[5] M. Walther,et al. Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia , 2017, Haematologica.
[6] M. Burbridge,et al. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies , 2017, Current Oncology Reports.
[7] Ø. Bruserud,et al. Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms , 2017, Front. Immunol..
[8] M. Wong,et al. FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. , 2016, Cancer research.
[9] M. Manz,et al. MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. , 2016, Blood.
[10] E. Pronier,et al. Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia , 2016, Nature Communications.
[11] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[12] D. Saul,et al. CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis , 2016, Leukemia.
[13] R. Flavell,et al. inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice. , 2016, Blood.
[14] H. Polzer,et al. Microenvironmental Hypoxia regulates FLT3 expression and biology in AML , 2015, Scientific Reports.
[15] B. Robert,et al. CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib‐resistant chronic myeloid leukaemia , 2015, The Journal of pathology.
[16] Elizabeth C. Townsend,et al. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia , 2015, Science Advances.
[17] M. Caligiuri,et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia , 2015, Leukemia.
[18] G. Bernardi,et al. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia , 2015, Clinical Cancer Research.
[19] K. Davies,et al. The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer , 2014, Nature Reviews Cancer.
[20] E. Rankin,et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET , 2014, Proceedings of the National Academy of Sciences.
[21] Sergei A. Vinogradov,et al. Direct measurement of local oxygen concentration in the bone marrow of live animals , 2014, Nature.
[22] Klaus H. Metzeler,et al. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy , 2013, Leukemia.
[23] P. Carmeliet,et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. , 2013, Blood.
[24] I. Dusanter-Fourt,et al. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. , 2013, Cancer research.
[25] M. Caligiuri,et al. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. , 2013, Blood.
[26] Yoko Tabe,et al. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. , 2013, Cancer letters.
[27] G. Nybakken,et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. , 2012, Blood.
[28] K. Pienta,et al. Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer , 2012, Molecular Cancer Research.
[29] Andrew Kasarskis,et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.
[30] A. Kazlauskas,et al. Axl is essential for VEGF‐A‐dependent activation of PI3K/Akt , 2012, The EMBO journal.
[31] J. Tamburini,et al. High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study , 2011, Haematologica.
[32] D. Bearss,et al. Targeting Axl and Mer Kinases in Cancer , 2011, Molecular Cancer Therapeutics.
[33] E. Lippert,et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. , 2011, Blood.
[34] E. Vellenga,et al. Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells. , 2011, Blood.
[35] B. Smith,et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. , 2011, Blood.
[36] Y. Hitoshi,et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. , 2010, Cancer research.
[37] Y. Hitoshi,et al. R 428 , a Selective Small Molecule Inhibitor of Axl Kinase , Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer , 2010 .
[38] R. Foà,et al. Interleukin (IL)‐3/granulocyte macrophage‐colony stimulating factor/IL‐5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS‐related tyrosine kinase 3 receptor , 2009, British journal of haematology.
[39] Ming-Tseh Lin,et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. , 2008, Cancer letters.
[40] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[41] H. Earp,et al. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.
[42] G. Lemke,et al. TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response , 2007, Cell.
[43] Chunaram Choudhary,et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. , 2006, Blood.
[44] W. Berdel,et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. , 2006, Haematologica.
[45] J. Dick,et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.
[46] Jeremy W. Linsley,et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. , 2006, Blood.
[47] J. Griffin,et al. The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.
[48] D. Howard,et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.
[49] S. Rafii,et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. , 2000, The Journal of clinical investigation.
[50] R. Herrmann,et al. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK) , 1999, Leukemia.
[51] I. Dusanter-Fourt,et al. Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin , 1996, Molecular and cellular biology.